{"ok":true,"api":{"name":"SAIMSARA Evidence Object Discovery API","version":"v1"},"mode":"doc_key","editorial_verification":{"status":"human_reviewed","trust_label":"machine_generated_human_reviewed","method":"World ID proof-of-human editorial account","scope":["clinical_integrity","reference_quality","scientific_coherence"],"verification_note":"This Evidence Object is machine-generated and human-reviewed. World ID is used to verify that editorial oversight was submitted by a unique human account.","does_not_mean":"World ID verifies proof-of-human editorial oversight; it does not independently certify the scientific truth of every claim."},"object":{"object_type":"saimsara_evidence_object_metadata","doc_key":"vascular::APIXABAN_VS_RIVAROXABAN","issue_slug":"vascular","doc_id":"APIXABAN_VS_RIVAROXABAN","title":"Apixaban vs Rivaroxaban","doi":"10.62487/saimsarae6ee9492","doi_url":"https://doi.org/10.62487/saimsarae6ee9492","version":"2026-05-02","source_name":"PubMed","article_url":"https://saimsara.com/sessions/apixaban-rivaroxaban-20260502-122006-e6ee9492/","image_url":"","topic_tags":"Apixaban,Rivaroxaban,Atrial Fibrillation,Venous Thromboembolism,Major Bleeding Risk,Ischemic Stroke,Gastrointestinal Bleeding,Direct Oral Anticoagulants,Comparative Effectiveness,Factor Xa Inhibitors, DOAC, NOAC","keywords":["Apixaban","Rivaroxaban","Atrial Fibrillation","Venous Thromboembolism","Major Bleeding Risk","Ischemic Stroke","Gastrointestinal Bleeding","Direct Oral Anticoagulants","Comparative Effectiveness","Factor Xa Inhibitors","DOAC","NOAC"],"metrics":{"included_all":1247,"included_original":995,"reference_index":177,"total_participants":26655215},"discover_url":"https://saimsara.com/api/v1/discover.php?doc_key=vascular%3A%3AAPIXABAN_VS_RIVAROXABAN","paid_evidence_url":"https://saimsara.com/api/v1/evidence.php?doc_key=vascular%3A%3AAPIXABAN_VS_RIVAROXABAN","price":{"amount":"5.00","currency":"USD","units":5,"unit_amount":"1.00"},"payment_methods":["api_key","stripe_checkout","object_grant","x402"],"text_length":28440,"preview":"Results Key finding aligned to the query: Apixaban consistently demonstrates a superior safety profile compared to rivaroxaban, particularly regarding a lower risk of major bleeding (MB) and gastrointestinal bleeding (GIB) across diverse populations. Large-scale cohort studies report hazard ratios (HR) for MB ranging from 0.50 to 0.86 in favor of apixaban, and a significantly lower risk of GIB (HR 0.33 to 0.72) compared to rivaroxaban. While effectiveness in preventing stroke or recurrent VTE is often comparable, several high-power analyses suggest apixaban may also provide superior protection against ischemic events in specific subgroups. Original research topic synthesis: Topics are presen…","trust_label":"machine_generated_human_reviewed","editorial_verification":{"status":"human_reviewed","trust_label":"machine_generated_human_reviewed","method":"World ID proof-of-human editorial account","scope":["clinical_integrity","reference_quality","scientific_coherence"],"verification_note":"This Evidence Object is machine-generated and human-reviewed. World ID is used to verify that editorial oversight was submitted by a unique human account.","does_not_mean":"World ID verifies proof-of-human editorial oversight; it does not independently certify the scientific truth of every claim."},"checkout":{"method":"POST","url":"https://saimsara.com/create_checkout_session.php","content_type":"application/x-www-form-urlencoded","params":{"plan":"evidence_object","doc_key":"vascular::APIXABAN_VS_RIVAROXABAN"},"optional_params":{"customer_email":"user@example.com"},"price":{"amount":"5.00","currency":"USD","units":5,"unit_amount":"1.00"},"curl_example":"curl -X POST https://saimsara.com/create_checkout_session.php -d \"plan=evidence_object\" -d \"doc_key=vascular::APIXABAN_VS_RIVAROXABAN\" -d \"customer_email=user@example.com\""},"access_after_payment":{"header":"X-SAIMSARA-Payment-Proof","endpoint":"https://saimsara.com/api/v1/evidence.php?doc_key=vascular%3A%3AAPIXABAN_VS_RIVAROXABAN","curl_example":"curl -H \"X-SAIMSARA-Payment-Proof: YOUR_PAYMENT_PROOF_TOKEN\" \"https://saimsara.com/api/v1/evidence.php?doc_key=vascular%3A%3AAPIXABAN_VS_RIVAROXABAN\""}}}